EUVIMEDEUVIMED entdecken
Crossref

PEGylation of New Thrombin Inhibitor Peptide Ultravariegin for Prolonged In Vivo Circulation and Enhanced Antithrombotic Effects

Xia Song iD, Yuting Wen iD, Aaron Wei Liang Li, Jingling Zhu iD, Cho Yeow Koh, R Manjunatha Kini, Mark Yan Yee Chan, Jun Li iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00769 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Xia Song und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore 119276, Singapore. Hauptthemen laut MEDLINE: Polyethylene Glycols, Antithrombins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China - State Grid Corporation Joint Fund for Smart Grid, Ministry of Education - Singapore, Natural Science Foundation of Chongqing, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anticoagulant therapy is commonly used to prevent and treat arterial and venous blood clots in patients with cardiovascular disease, cerebrovascular disease, and cancer. Venous blood clots are the third leading cause of cardiovascular death following acute coronary artery disease and stroke. There is a significant need for effective anticoagulant therapy with minimal risk of bleeding. Variegin and its variants are a new type of antithrombin peptide that has shown promising results in preclinical studies. Variegin and its best variant, ultravariegin (UV), can more effectively inhibit blood clot formation while causing less bleeding than traditional medications such as heparin and bivalirudin. However, the short lifespan of UV remains a limitation for its use in clinical settings. PEGylation, a method of conjugating poly(ethylene glycol) (PEG) chains to peptides or drugs, may help improve the effectiveness of UV by extending its circulation time in the body. In this study, UV was PEGylated using maleimide-PEG5k and 10k. The impact of PEGylation on the antithrombin activity of UV was assessed in vitro and ex vivo in rat and rabbit plasma, showing minimal effects on the efficacy. In vivo studies in rats and rabbits revealed that PEGylated UV had a longer half-life and greater anticoagulant effects than unmodified UV did, especially when it was administered subcutaneously. PEGylation significantly extended the half-life of UV in rabbits, resulting in sustained anticoagulant effects for up to 4 days. This demonstrated that increasing the size of UV and shielding it with PEG could reduce clearance by the kidneys and prolong its circulation time. The improved half-life and antithrombin activity of PEGylated UV make it a more favorable choice for anticoagulant therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyethylene GlycolsAntithrombinsAnimalsRatsRabbitsMaleRats, Sprague-DawleyFibrinolytic AgentsHumansAnticoagulantsBlood CoagulationThrombinPeptidesThrombosis

Stichwörter der Autor:innen

PEGylationanticoagulant peptideantithrombin efficacyin vivo circulationthrombin inhibitorultravariegin

Substanzen

Polyethylene GlycolsAntithrombinsFibrinolytic AgentsAnticoagulantsThrombinPeptides

Autor:innen und Institutionen

  • Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore 119276, Singapore.
  • National University of Singapore (Chongqing) Research Institute, Yubei District, Chongqing 401120, China.
  • National University of Singapore (Suzhou) Research Institute, Suzhou, Jiangsu 215123, China.
  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore.
  • NUS Environmental Research Institute (NERI), National University of Singapore, Singapore 117411, Singapore.
  • Department of Biological Sciences, National University of Singapore, Singapore 117543, Singapore.

ORCID-Profile: Xia Song, Yuting Wen, Jingling Zhu, Jun Li

Förderung

  • National Natural Science Foundation of China - State Grid Corporation Joint Fund for Smart Grid
  • Ministry of Education - Singapore
  • Natural Science Foundation of Chongqing, China
  • Science and Technology Project of Jiangsu Province, China

Zitieren

APA

Song, X., Wen, Y., Li, A. W. L., Zhu, J., Koh, C. Y., Kini, R. M., Chan, M. Y. Y., & Li, J. (2024). PEGylation of New Thrombin Inhibitor Peptide Ultravariegin for Prolonged In Vivo Circulation and Enhanced Antithrombotic Effects. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00769

Vancouver

Song X, Wen Y, Li AWL, Zhu J, Koh CY, Kini RM, et al. PEGylation of New Thrombin Inhibitor Peptide Ultravariegin for Prolonged In Vivo Circulation and Enhanced Antithrombotic Effects. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00769

BibTeX
@article{Song2024,
  author = {Song, Xia and Wen, Yuting and Li, Aaron Wei Liang and Zhu, Jingling and Koh, Cho Yeow and Kini, R Manjunatha and Chan, Mark Yan Yee and Li, Jun},
  title = {PEGylation of New Thrombin Inhibitor Peptide Ultravariegin for Prolonged In Vivo Circulation and Enhanced Antithrombotic Effects},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00769}
}
Kostenlos starten →